^
    Back
    Association details:
    Biomarker:DNMT1 expression + PARP1 expression
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Gynecol Oncol
    Title:

    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer

    Published date:
    03/16/2022
    Excerpt:
    Expression levels of DNMT1 and PARP1 proteins in EOC cells were assessed using western blot analysis and immunohistochemistry...The combination of olaparib and 5-AZA significantly inhibited cell proliferation and migration and induced apoptosis compared with olaparib or 5-AZA alone in EOC cell lines...
    Secondary therapy:
    azacitidine
    DOI:
    https://doi.org/10.1016/j.ygyno.2022.03.005